Cilostazol This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This page shows you the latest news and research items in this category.
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent
Abstract: It has been shown that triple antiplatelet therapy with cilostazol results in better clinical outcomes than dual therapy in patients treated with a first-generation drug-eluting stent (DES); however, it is unclear whether triple antiplatelet therapy has a similar efficacy after the implantation of second-generation DES. In the COACT (Cath Olic medical center percutAneous Coronary in Tervention) registry, 1248 study subjects who underwent percutaneous coronary intervention with an everolimus- or zotarolimus-eluting stent (Endeavor, Xience V, or Promus) were analyzed. The patients were divided into 2 groups after p...
Source: Medicine - November 1, 2015 Category: Internal Medicine Tags: Observational Study Source Type: research
Cilostazol inhibits interleukin-1-induced ADAM17 expression through cAMP independent signaling in vascular smooth muscle cells.
Abstract Increased a disintegrin and metalloprotease 17 (ADAM17) expression in vascular smooth muscle cells (VSMC) is implicated in the development of cardiovascular diseases including atherosclerosis and hypertension. Although cilostazol, type phosphodiesterase (PDE?) inhibitor, has recently been found to inhibit VSMC proliferation, the mechanisms remain largely unclear. Here we hypothesized that cilostazol regulates the ADAM17 expression in VSMC. In cultured VSMC, interleukin (IL)-1α and IL-1β significantly increased ADAM17 expression. MEK inhibitor U0126, NF-κB inhibitor BAY-11-7085 and siRNA targeting p65/Re...
Source: Cell Biology International - October 30, 2015 Category: Cytology Authors: Takaguri A, Morimoto M, Imai SI, Satoh K Tags: Cell Biol Int Source Type: research
CILOSTAZOL Tablet [Eon Labs, Inc.]
Updated Date: Oct 28, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 28, 2015 Category: Drugs & Pharmacology Source Type: news
Cilostazol blocks pregnancy in naturally cycling swine: An animal model
This study shows that CLZ is capable of producing a reversible non-steroidal contraceptive effect without adverse effects on the heart rate in pigs. The observed contraceptive effect of CLZ was at doses similar to those indicated to humans. This FDA approved agent, for treatment of patients with intermittent claudication, may have an additional therapeutic effect as a non-steroidal contraceptive agent. Cilostazol merits further evaluation in women. (Source: Life Sciences)
Source: Life Sciences - October 23, 2015 Category: Biology Source Type: research
Serum Uric Acid Is Associated with Cerebral White Matter Hyperintensities in Patients with Acute Lacunar Infarction
CONCLUSIONSThis study showed that serum UA was associated with cerebral WMH in patients with acute lacunar infarction. (Source: Journal of Neuroimaging)
Source: Journal of Neuroimaging - October 13, 2015 Category: Radiology Authors: Sang Won Han, Tae Jin Song, Cheryl D. Bushnell, Sung‐Soo Lee, Seo Hyun Kim, Jun Hong Lee, Gyu Sik Kim, Ok‐Joon Kim, Im‐Seok Koh, Jong Yun Lee, Seung‐Han Suk, Sung Ik Lee, Hyo Suk Nam, Kyung‐Yul Lee, Jae Hyeon Park Tags: Clinical Investigative Study Source Type: research
The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes
ConclusionsAdditive antiplatelet effect of cilostazol to clopidogrel is maximized in subjects with both CYP2C19PM and CYP3A5*3/*3 because of lack of change of clopidogrel thiol metabolite exposure in CYP3A5*3/*3 as well as the highest cilostazol IPA in CYP2C19 PM or CYP3A5*3/*3. This article is protected by copyright. All rights reserved. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - October 1, 2015 Category: Drugs & Pharmacology Authors: Ho‐Sook Kim, Younghae Lim, Minkyung Oh, Jong‐lyul Ghim, Eun‐Young Kim, Dong‐Hyun Kim, Jae‐Gook Shin Tags: Drug Interactions Source Type: research
Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention.
In conclusion, low-dose adjunctive cilostazol seems superior to dual antiplatelet therapy in reducing recurrent ischemic events in patients with complex coronary lesions and two groups have similar incidence of bleeding events. This article is protected by copyright. All rights reserved. PMID: 26414108 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - September 28, 2015 Category: Drugs & Pharmacology Authors: Zheng XT, Chen KY, Liu T, Xu LX, Che JJ, Rha SW, Li GP Tags: Clin Exp Pharmacol Physiol Source Type: research
The Latest Information on Intracranial Atherosclerosis: Diagnosis and Treatment
Intracranial atherosclerotic stenosis (ICAS) is the most common cause of ischemic stroke in the world. ICAS is especially common in the Asian population accounting for 30-50% of all ischemic strokes. The risk of recurrent stroke in patients with symptomatic ICAS is the highest among the stroke subtypes. Two major factors associated with recurrent stroke are high degree (>70%) of stenosis and progression of ICAS. Transcranial Doppler ultrasound, CT angiography, MR angiography, and conventional catheter angiography are used for the diagnosis of ICAS. Today, high-resolution MRI can provide important information to improve the...
Source: Interventional Neurology - September 18, 2015 Category: Neurology Source Type: research
Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
This study was designed to investigate the effects of cilostazol on the pharmacokinetics of carvedilol following oral or intravenous administration of carvedilol in rats. Clinically carvedilol and cilostazol can be prescribed for treatment of cardiovascular diseases. Carvedilol and cilostazol are all substrates of CYP2C9 enzymes. Carvedilol was administered orally or intravenously without or with oral administration of cilostazol to rats. The effects of cilostazol on cytochrome P450 (CYP) 2C9 activity and P-gp activity were also evaluated. Cilostazol inhibited CYP2C9 activity in a concentration-dependent manner with 50% in...
Source: Journal of Physiology and Pharmacology - September 11, 2015 Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats
This study also revealed that cilostazol promotes angiogenesis, and L-carnitine additively contributes to functional improvement via a non-angiogenic mechanism.Pharmacology 2015;96:210-216 (Source: Pharmacology)
Source: Pharmacology - September 1, 2015 Category: Drugs & Pharmacology Source Type: research
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials
To assess the long-term clinical efficacy and safety of adding cilostazol (TAT) to conventional dual antiplatelet therapy (DAT) for patients undergoing drug-eluting stent (DES) implantation in coronary arteries. (Source: Thrombosis Research)
Source: Thrombosis Research - August 27, 2015 Category: Hematology Authors: Yandun Zou, Chunling Hu, Wenhui Ye, Limei Fan, Likun Xu, Aidong Zhang Tags: Full Length Article Source Type: research
Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings
Abstract Numerous interventions have been shown to limit myocardial infarct size in animal models; however, most of these interventions have failed to have a significant effect in clinical trials. One potential explanation for the lack of efficacy in the clinical setting is that in bench models, a single intervention is studied without the background of other interventions or modalities. This is in contrast to the clinical setting in which new medications are added to the “standard of care” treatment that by now includes a growing number of medications. Drug-drug interaction may lead to alteration, dampening, ...
Source: Cardiovascular Drugs and Therapy - August 25, 2015 Category: Cardiology Source Type: research
Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis [Stroke]
Conclusions Long-term monotherapy was a better choice than long-term dual therapy, and cilostazol had the best risk–benefit profile for long-term secondary prevention after stroke or transient ischemic attack. More randomized controlled trials in non–East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke. (Source: JAHA:Journal of the American Heart Association)
Source: JAHA:Journal of the American Heart Association - August 24, 2015 Category: Cardiology Authors: Xie, W., Zheng, F., Zhong, B., Song, X. Tags: Stroke Source Type: research
Suppression of RANKL-induced osteoclast differentiation by cilostazol via SIRT1-induced RANK inhibition
In conclusion, cilostazol activates SIRT1, which suppresses the nuclear translocation of PU.1, and thus, inhibits RANKL-stimulated RANK expression and causes anti-osteoclast formation in BMMs in vitro and in their murine model of CIA. (Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease)
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - August 13, 2015 Category: Molecular Biology Source Type: research
Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease
Efficacy of endovascular therapy (EVT) with nitinol stents for femoropopliteal (FP) lesions is limited by restenosis. Oral cilostazol reduces angiographic restenosis rate; however, treatment duration remains unclear. In a retrospective analysis of a multicenter database of 3471 consecutive limbs in 2737 patients (mean age: 72 ± 9 years; 61% diabetic; and 26% on regular dialysis) undergoing EVT for FP lesions between January 2004 and December 2011, we compared Kaplan-Meier estimated primary patency after EVT followed or not by cilostazol treatment. We used Cox hazard regression analysis to assess temporal association...
Source: Angiology - August 12, 2015 Category: Cardiology Authors: Nanto, K., Iida, O., Takahara, M., Soga, Y., Suzuki, K., Hirano, K., Kawasaki, D., Shintani, Y., Suematsu, N., Yamaoka, T., Uematsu, M. Tags: Peripheral Artery Disease Source Type: research
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits
Conclusions: These data demonstrated that combined drug treatment exhibits potent athero-protective effects via pleiotropic functions, such as anti-inflammatory and anti-oxidative stress, which is independent of the lipid-lowering effect. (Source: Lipids in Health and Disease)
Source: Lipids in Health and Disease - July 29, 2015 Category: Lipidology Authors: Yanli WangLiang BaiYan LinYulong ChenHua GuanNinghong ZhuYafeng LiShoucui GaoLijing SunSihai ZhaoJianglin FanEnqi Liu Source Type: research
Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis
Cilostazol, a phosphodiesterase 3, has been widely used in patients with arterial disease and is known to have additional beneficial effects on dyslipidemia. However, the effect of cilostazol on hepatic steatosis has not been fully elucidated. We investigated the effect of cilostazol on hepatic ABCA1 expression and hepatic steatosis in diet-induced obesity mice model. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - July 24, 2015 Category: Biomedical Science Authors: Byung Hun Jeon, Yong-ho Lee, Mi Ra Yun, Soo Hyun Kim, Byung Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong-Soo Cha Source Type: research
Intimal exfoliation Following Abnormal Circular Proliferation as a Cause for Acute Coronary Syndrome in a Patient with Polycythemia Vera
A 78-year-old female with a history of polycythemia vera (PV) was admitted due to sudden severe chest pain at rest. She had been treated with 500mg/day of hydroxycarbamide for PV (platelet counts ranging from 480,000 to 600,000/μl, leukocyte counts ranging from 14,500 to 18,000/μl, and hematocrit levels ranging from 37 to 42 %), and 100mg/day of cilostazol for previous cerebral transient ischemia attack. Physical examination revealed no specific findings except splenomegaly. Anterior ST-segment elevation myocardial infarction (STEMI) was diagnosed by electrocardiography. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - July 19, 2015 Category: Cardiology Authors: Tsuyoshi Nishiguchi, Atsushi Tanaka, Takashi Yamano, Takashi Kubo, Takashi Akasaka Source Type: research
Protective effect of cilostazol on doxorubicin-induced cardiomyopathy in mice.
Abstract Doxorubicin (Dox) is an effective anti-cancer drug, but its use is limited due to the adverse effect by inducing the irreversible dilated cardiomyopathy. Cilostazol (Cilo), a potent phosphodiesterase III inhibitor, has been reported to have an anti-inflammatory effect. Here, we investigated whether Cilo has a protective effect on Dox-induced cardiomyopathy (DIC). The mice were randomly divided into four groups: saline-control, Dox (15mg/kg), Dox (15mg/kg) plus Cilo (50mg/kg), and Cilo (50mg/kg). As results, the co-administration of Dox and Cilo significantly enhanced the left ventricular systolic function ...
Source: Free Radical Biology and Medicine - July 18, 2015 Category: Biology Authors: Sin Koh J, Yi CO, Won Heo R, Ahn JW, Rang Park J, Eun Lee J, Kim JH, Hwang JY, Seob Roh G Tags: Free Radic Biol Med Source Type: research
Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model.
CONCLUSIONS: Cilostazol prevents stenosis of bioresorbable vascular graft in a mouse inferior vena cava implantation model up to 24 weeks and is accompanied by reduction of smooth muscle cell proliferation and acute inflammation. PMID: 26183618 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - July 16, 2015 Category: Cardiology Authors: Tara S, Kurobe H, de Dios Ruiz Rosado J, Best CA, Shoji T, Mahler N, Yi T, Lee YU, Sugiura T, Hibino N, Partida-Sanchez S, Breuer CK, Shinoka T Tags: Arterioscler Thromb Vasc Biol Source Type: research
New therapeutic effects of cilostazol in patients with ischemic disorders.
The objective of the present review is to analyze the existing data about the therapeutic effects of CIL, with the purpose of providing practical indications about this topic for the management of subjects affected by ischemic disorders. PMID: 26156267 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - July 11, 2015 Category: Drugs & Pharmacology Authors: Biscetti F, Ferraccioli G, Flex A Tags: Curr Vasc Pharmacol Source Type: research
Understanding the role of antioxidant therapy for intermittent claudication; Good, bad, or both?
Abstract Peripheral arterial disease (PAD) is a global health issue, affecting 202 million people worldwide. The most common symptom of PAD is intermittent claudication (IC), which is associated with increased risk of cardiovascular morbidity and mortality, and thus is an area where new therapies are urgently needed. Currently the only FDA-approved medications for treating PAD-associated walking impairment are pentoxifylline and cilostazol. However, these agents have been shown to produce only minimal improvement in maximal treadmill walking distance. Much evidence exists for a role of oxidant stress and inflammati...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 10, 2015 Category: Physiology Authors: Miller SJ, Unthank JL Tags: Am J Physiol Heart Circ Physiol Source Type: research
Stimulation of angiogenesis by cilostazol accelerates fracture healing in mice
This article is protected by copyright. All rights reserved (Source: Journal of Orthopaedic Research)
Source: Journal of Orthopaedic Research - July 1, 2015 Category: Orthopaedics Authors: Steven C. Herath, Thorsten Lion, Moritz Klein, David Stenger, Claudia Scheuer, Jörg H. Holstein, Philipp Mörsdorf, Mika F.R. Rollmann, Tim Pohlemann, Michael D. Menger, Tina Histing Tags: Research Article Source Type: research
Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis
Hepatic ischemia-reperfusion (I/R) can cause hepatocellular injury associated with the inflammatory response and mitochondrial dysfunction. We studied the protective effects of the phosphodiesterase inhibitor cilostazol in hepatic I/R and the roles of mitochondria and the Nrf2/heme oxygenase-1 (HO-1) system. Wild-type, Hmox1–/–, or Nrf2–/– mice were subjected to hepatic I/R in the absence or presence of cilostazol followed by measurements of liver injury. Primary hepatocytes were subjected to cilostazol with the HO-1 inhibitor ZnPP, or Nrf2-specific siRNA, followed by assessment of mitochondrial bio...
Source: AJP: Gastrointestinal and Liver Physiology - July 1, 2015 Category: Gastroenterology Authors: Joe, Y., Zheng, M., Kim, H. J., Uddin, M. J., Kim, S.-K., Chen, Y., Park, J., Cho, G. J., Ryter, S. W., Chung, H. T. Tags: LIVER AND BILIARY TRACT Source Type: research
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry
Abstract The efficacy and safety of adding cilostazol to aspirin plus clopidogrel (triple antiplatelet therapy, TAPT) have not been fully evaluated in complex percutaneous coronary intervention (PCI). We sought to investigate whether TAPT after PCI for bifurcation lesions improves long-term clinical outcomes. Consecutive patients undergoing PCI for bifurcation lesions were enrolled from 18 centers in Korea between 2003 and 2009. We compared target vessel failure (TVF), defined as a composite of cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR), among 675 patients who received TA...
Source: Heart and Vessels - July 1, 2015 Category: Cardiology Source Type: research
Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients
Abstract Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud’s phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one consecutive SSc patients with moderate or severe RP were enrolled in an open-label study. Cilostazol was administered at the dose of 100 mg twice a day, for 12 months. Evaluations included: daily RP attack diary documenting the frequency and duration of RP episodes, H...
Source: Clinical and Experimental Medicine - June 19, 2015 Category: Research Source Type: research
Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol
In conclusion, crystal engineering by habit modification show potential for dissolution enhancement with an added advantage of improved flow properties over micronization technique, for poorly soluble drugs like cilostazol. Graphical abstract (Source: International Journal of Pharmaceutics)
Source: International Journal of Pharmaceutics - June 18, 2015 Category: Drugs & Pharmacology Source Type: research
Cilostazol inhibits HMGB1 release in LPS-activated RAW 264.7 cells and increases the survival of septic mice
Inflammation and coagulation play important roles in the pathogenesis of sepsis. Anticoagulants with anti-inflammatory action draw attention as therapeutic agent in sepsis. (Source: Thrombosis Research)
Source: Thrombosis Research - June 15, 2015 Category: Hematology Authors: Ki Churl Chang Source Type: research
Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
CONCLUSIONS: Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD. PMID: 26074442 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)
Source: Journal of Cardiology - June 11, 2015 Category: Cardiology Authors: Ishii H, Aoyama T, Takahashi H, Kumada Y, Kamoi D, Sakakibara T, Umemoto N, Suzuki S, Tanaka A, Ito Y, Murohara T Tags: J Cardiol Source Type: research
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial
DiscussionPreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage is the largest secondary stroke prevention trial for informing antiplatelet therapy and lipid management in patients at high risk of haemorrhagic stroke. (Source: International Journal of Stroke)
Source: International Journal of Stroke - June 4, 2015 Category: Neurology Authors: Keun‐Sik Hong, Bum Joon Kim, Jun‐Young Lee, Sun U. Kwon, Tags: Protocol Source Type: research
Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia
Publication date: August 2015 Source:Pharmacology Biochemistry and Behavior, Volume 135 Author(s): Ashwani Kumar , Amit Kumar , Amteshwar S. Jaggi , Nirmal Singh The present study has been designed to investigate the potential of Cilostazol a phosphodiesterase-3 (PDE-3) inhibitor in diabetes-induced vascular dementia (Vad) employing Wistar rats. A single dose of Streptozotocin (STZ) was used for the induction of diabetes and subsequent Vad in rats. Memory and learning abilities of rats were evaluated with Morris water maze (MWM) test. Serum glucose, body weight, vascular endothelial function, serum nitrite/nitrate levels...
Source: Pharmacology Biochemistry and Behavior - May 31, 2015 Category: Biochemistry Source Type: research
Use of Whole Exome Sequencing for the Identification of Ito-Based Arrhythmia Mechanism and Therapy [Molecular Cardiology]
Conclusions We describe a novel arrhythmia mechanism and therapeutic approach to ameliorate the disease. Specifically, we identify the first coding variant of DPP6 in human ventricular fibrillation. These findings illustrate the power of genetic approaches for the elucidation and treatment of disease when carefully integrated with clinical and basic/translational research teams. (Source: JAHA:Journal of the American Heart Association)
Source: JAHA:Journal of the American Heart Association - May 26, 2015 Category: Cardiology Authors: Sturm, A. C., Kline, C. F., Glynn, P., Johnson, B. L., Curran, J., Kilic, A., Higgins, R. S. D., Binkley, P. F., Janssen, P. M. L., Weiss, R., Raman, S. V., Fowler, S. J., Priori, S. G., Hund, T. J., Carnes, C. A., Mohler, P. J. Tags: Molecular Cardiology Source Type: research
Cilostazol Bridges Surgical DES Patients Without DAPTCilostazol Bridges Surgical DES Patients Without DAPT
Based on long-term follow-up in an observational study, the PDE-3 inhibitor was called an "ingenious bridge" for patients taken off standard dual-antiplatelet therapy during surgery. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 11, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Cilostazol Attenuates Murine Hepatic Ischemia and Reperfusion Injury via Heme Oxygenase-Dependent Activation of Mitochondrial Biogenesis.
Abstract Hepatic ischemia/reperfusion (I/R) can cause hepatocellular injury associated with the inflammatory response and mitochondrial dysfunction. We studied the protective effects of the phosphodiesterase inhibitor cilostazol in hepatic I/R, and the roles of mitochondria, and the Nrf2/ heme oxygenase-1 (HO-1) system. Wild type, Hmox1(-/-) or Nrf2(-/-) mice were subjected to hepatic I/R in the absence or presence of cilostazol followed by measurements of liver injury. HepG2 cells were subjected to cilostazol with the HO-1 inhibitor ZnPP, or Nrf2 specific siRNA, followed by assessment of mitochondrial biogenesis. ...
Source: Am J Physiol Gastroi... - May 7, 2015 Category: Gastroenterology Authors: Joe Y, Zheng M, Kim HJ, Uddin MJ, Kim SK, Chen Y, Park J, Cho GJ, Ryter SW, Chung HT Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research
CILOSTAZOL Tablet [Golden State Medical Supply, Inc.]
Updated Date: May 5, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - May 5, 2015 Category: Drugs & Pharmacology Source Type: news
Cilostazol improves hepatic blood perfusion, microcirculation, and liver regeneration after major hepatectomy in rats
In conclusion, cilostazol increases hepatic blood perfusion, microcirculation, and liver regeneration after a major hepatectomy. Thus, cilostazol may represent a novel strategy to reduce the rate of liver failure after both extended hepatectomy and small‐for‐size liver transplantation. Liver Transpl, 2015. © 2015 AASLD. (Source: Liver Transplantation)
Source: Liver Transplantation - May 4, 2015 Category: Transplant Surgery Authors: Maximilian von Heesen, Stefan Dold, Simon Müller, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger, Mohammed R. Moussavian Tags: Original Article Source Type: research
An experimental study of the effect of pre-operative administration of cilostazol on random skin flap survival in rats: double blinded randomized controlled trial
Background: Insufficient arterial blood flow is the one cause of flap necrosis. Cilostazol is an inhibitor of phosphodiesterase III and increases cyclic AMP level in vascular smooth muscle cell causing vasodilation. Therefore, effect of cilostazol is expected to improve the viability of the flap. Methods: Double blinded randomized controlled trial was conducted. The study was to compare the survival of dorsal rat flaps between preoperative cilostazol supplemented diet and regular diet. The flap survival area was measured using PixArea Image software on post operative day 1,3,5 and 7. Fluorescein injection was performed to ...
Source: BioMed Central - April 28, 2015 Category: Journals (General) Authors: Chairat BurusapatJanjira PaengnoiKantang Satayasoontorn Source Type: research
When Should Cilostazol (Pletal) and Dipyridamole Be Discontinued Before Neuroaxial Block?
No abstract available (Source: Regional Anesthesia and Pain Medicine)
Source: Regional Anesthesia and Pain Medicine - April 24, 2015 Category: Anesthesiology Tags: Letters to the Editor Source Type: research
Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study
Despite established clinical efficacy of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor in acute coronary syndrome (ACS) patients, persistent recurrent ischemic event (~10% during 1year) suggests a ceiling effect in attenuating ischemic events and some clinical events are mediated by other pathways . Cilostazol is a unique dual inhibitor of phosphodiesterase 3 (PDE3) and adenosine reuptake . It also provides vasodilation, enhances endothelial function, inhibits neointimal hyperplasia and in-stent restenosis, decreases various inflammatory pathways, improves lipid profile, and has cardiop...
Source: International Journal of Cardiology - April 23, 2015 Category: Cardiology Authors: Kyounghoon Lee, Sang-Yong Yoo, Jon Suh, Keun Ho Park, Yongwhi Park, Udaya S. Tantry, Ki-Soo Park, Seung Hwan Han, Woong Chol Kang, Dae-Hee Shin, Changkun Lee, Si Wan Choi, Jae-Hwan Lee, Yoon Haeng Cho, Nae-Hee Lee, Myung Ho Jeong, Youngkeun Ahn, Jacek Kub Tags: Letter to the editor Source Type: research
Improvement in in vitro fertilization outcome following in vivo synchronization of oocyte maturation in mice
This study was therefore designed to define the effect of in vivo synchronization of oocyte maturation on IVF rates. Mice were superovulated and orally treated with 7.5 mg cilostazol (CLZ), a phosphodiesterase 3A (PDE3A) inhibitor, to induce ovulation of immature oocytes at different stages depending on frequency and time of administration of CLZ. Mice treated with CLZ ovulated germinal vesicle (GV) or metaphase I (MI) oocytes that underwent maturation in vitro or in vivo (i.e. in the oviduct) followed by IVF. Superovulated control mice ovulated mature oocytes that underwent IVF directly upon collection. Ovu...
Source: Experimental Biology and Medicine - April 15, 2015 Category: Research Authors: Taiyeb, A. M., Muhsen-Alanssari, S. A., Dees, W., Ridha-Albarzanchi, M. T., Kraemer, D. C. Tags: Pharmacology/Toxicology Source Type: research
Serum uric acid is positively associated with cerebral white matter hyperintensities in patients with acute lacunar infarction: Subgroup analysis of the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study (P1.046)
CONCLUSIONS: This study showed that WMH volume was positively associated with serum UA in patients with acute lacunar infarction. Our findings indicate that impaired cerebrovascular hemodynamics may be associated with cerebral WMH. Study Supported by: NoneDisclosure: Dr. Han has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Park has nothing to disclose. Dr. Park has nothing to disclose. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Han, S. W., Lee, J. Y., Lee, K.-Y., Park, J. H., Park, J. H. Tags: Cerebrovascular Disease and Interventional Neurology: The Spectrum of Small Vessel Cerebrovascular Disease Source Type: research
CILOSTAZOL Tablet [Golden State Medical Supply, Inc.]
Updated Date: Mar 30, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 30, 2015 Category: Drugs & Pharmacology Source Type: news
Preconditioning by Cilostazol Protects against Cold Hepatic Ischemia-Reperfusion Injury.
Conclusions Inhibition of PDE3 reduces endothelial cell activation and hepatocellular injury in cold ischemia/reperfusion of the liver. PMID: 25811412 [PubMed - as supplied by publisher] (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 27, 2015 Category: Transplant Surgery Authors: von Heesen M, Müller S, Keppler U, Strowitzki MJ, Scheuer C, Schilling MK, Menger MD, Moussavian MR Tags: Ann Transplant Source Type: research
Retraction Note: Systematic study of cilostazol on secondary stroke prevention: a meta-analysis
(Source: European Journal of Medical Research)
Source: European Journal of Medical Research - March 26, 2015 Category: Research Source Type: research
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
CONCLUSIONS: Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. This could be a novel strategy for cardioembolic stroke prevention potentially by affecting cardiac remodelling, in contrast to secondary anticoagulant therapy. PMID: 25798683 [PubMed - as supplied by publisher] (Source: Neurological Research)
Source: Neurological Research - March 24, 2015 Category: Neurology Tags: Neurol Res Source Type: research
Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
Antiplatelet therapy is recommended for patients who have experienced ischemic stroke. We performed a meta-analysis to compare the efficacy and safety of cilostazol with other antiplatelet therapies in patients with ischemic stroke. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - March 24, 2015 Category: Neurology Authors: Liang Tan, Barnhart Margaret, John H. Zhang, Rong Hu, Yi Yin, Liu Cao, Hua Feng, Yanqi Zhang Source Type: research
Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke: Pooled Analysis of Randomized Trials [Clinical Sciences]
Conclusions— Our results suggest that any of the single antiplatelet agents compared with placebo in the included trials is adequate for secondary stroke prevention after lacunar stroke. Dual antiplatelet therapy should not be used for long-term stroke prevention in this stroke subtype. (Source: Stroke)
Source: Stroke - March 23, 2015 Category: Neurology Authors: Kwok, C. S., Shoamanesh, A., Copley, H. C., Myint, P. K., Loke, Y. K., Benavente, O. R. Tags: Antiplatelets Clinical Sciences Source Type: research
Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial
Optimal strategy for the management of high on-treatment platelet reactivity (HPR), an independent predictor of ischaemic events, is not yet clear. The aim of this study was to explore the safety and efficacy of personalized antiplatelet therapy based on platelet function testing in patients with HPR. A total of 840 patients with HPR who underwent coronary stenting for acute coronary syndrome (ACS) were randomly assigned in a 1:2 ratio to receive standard dual-antiplatelet therapy (n = 280) or platelet function-guided optimal-antiplatelet therapy (n = 560). In the optimal group, patients initially received clopidogrel 150 ...
Source: European Journal of Heart Failure Supplements - March 23, 2015 Category: Cardiology Authors: Li, Y., Han, Y., Guan, S., Sun, Y., Guo, L., Yang, B., Zang, H., Jing, Q., Wang, X., Ma, Y., Liu, X., Li, J., Zheng, L. Tags: Articles Source Type: research
CILOSTAZOL Tablet [Apotex Corp.]
Updated Date: Mar 13, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 13, 2015 Category: Drugs & Pharmacology Source Type: news